Business Context and Reporting Period
This Form 8-K Current Report was filed by Editas Medicine, Inc. on May 11, 2023, regarding events occurring on May 16, 2023. The filing discloses a significant change in executive leadership, specifically the appointment of a new Chief Financial Officer and the departure of the incumbent.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and separation terms.
- New CFO Base Salary: $470,000 annually.
- New CFO Target Bonus: 45% of base salary (prorated for 2023).
- Outgoing CFO Severance: 12 months of base salary following the separation date.
Material Changes
The primary material change is the transition of the Chief Financial Officer role:
- Departure: Michelle Robertson stepped down as Executive Vice President and Chief Financial Officer effective May 16, 2023.
- Appointment: Erick J. Lucera was appointed Executive Vice President and Chief Financial Officer, effective May 17, 2023.
- Transition: Ms. Robertson will remain with the company through a transition period ending August 16, 2023.
Guidance, Outlook, and Compensation Details
The filing details the compensatory arrangements for the new CFO and the separation agreement for the outgoing CFO.
New CFO Compensation (Erick J. Lucera)
- Equity Grants:
- Option to purchase 155,800 shares (25% vesting on first anniversary, remainder over 36 months).
- Restricted Stock Units (RSUs) for 77,900 shares (vesting over four years).
- Performance-based RSUs for 77,900 shares (vesting upon achievement of R&D milestones by March 2, 2026).
- Severance: Entitled to benefits under the Company's Amended Severance Benefits Plan.
Outgoing CFO Separation (Michelle Robertson)
- Severance Period: 12 months of base salary following the August 16, 2023 separation date.
- Benefits: Company contributions to health care continuation during the severance period.
- Stock Options: Exercise period for vested options extended to August 16, 2024.
- Conditions: Payments are contingent upon the execution of a release of claims agreement.
Investor Verification Checklist
- Verify the exact vesting schedule and performance milestones for Mr. Lucera's equity grants.
- Confirm the total cash severance obligation for Ms. Robertson based on her final base salary.
- Review the Company's Amended Severance Benefits Plan (Exhibit 10.29 to the 2022 10-K) for details on Mr. Lucera's potential severance.
- Monitor the transition period ending August 16, 2023, for any operational disruptions.